We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.79B
AUM Growth
-$283M
Cap. Flow
-$93.2M
Cap. Flow %
-3.34%
Top 10 Hldgs %
67.96%
Holding
104
New
24
Increased
12
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$20M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.2M
3
GM icon
General Motors
GM
+$9.45M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.46M
5
CCI icon
Crown Castle
CCI
+$7.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$21.4M
2
ACOR
Acorda Therapeutics
ACOR
+$12.8M
3
F icon
Ford
F
+$10.1M
4
TEX icon
Terex
TEX
+$9.24M
5
UAL icon
United Airlines
UAL
+$8.76M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 34.56%
2 Healthcare 22.3%
3 Financials 0.62%
4 Real Estate 0.57%
5 Materials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
F icon
26
CALL
Ford
F
$61.4B
$20.1M 0.72%
1,300,000
+200,000
+18% +$3.35M
XBI icon
27
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$19.5M 0.7%
+450,000
New +$18.6M
ITB icon
28
CALL
iShares US Home Construction ETF
ITB
$2.34B
$18.6M 0.67%
750,000
+250,000
+50% +$5.66M
NKTR icon
29
Nektar Therapeutics
NKTR
$2.3B
$18.2M 0.65%
106,667
-46,666
-30% -$7.53M
VMC icon
30
CALL
Vulcan Materials
VMC
$36.8B
$17.8M 0.64%
+300,000
New +$16.6M
PCYC
31
DELISTED
PHARMACYCLICS INC
PCYC
$17.5M 0.63%
+165,000
New +$20M
AMGN icon
32
Amgen
AMGN
$210B
$17.1M 0.61%
150,000
– –
MJN
33
CALL
DELISTED
Mead Johnson Nutrition Company
MJN
$16.8M 0.6%
200,000
-50,000
-20% -$4.07M
CL icon
34
CALL
Colgate-Palmolive
CL
$74.2B
$16.3M 0.58%
+250,000
New +$16M
C icon
35
CALL
Citigroup
C
$216B
$15.6M 0.56%
300,000
-100,000
-25% -$5.06M
UAL icon
36
CALL
United Airlines
UAL
$39.4B
$15.1M 0.54%
+400,000
New +$14M
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$15M 0.54%
3,000,000
– –
ONIT
38
CALL
Onity Group
ONIT
$343M
$13.9M 0.5%
16,667
-13,333
-44% -$11M
XOMA
39
DELISTED
Xoma
XOMA
$13.5M 0.48%
100,000
-25,000
-20% -$2.52M
GS icon
40
CALL
Goldman Sachs
GS
$294B
$13.3M 0.48%
75,000
– –
GM icon
41
CALL
General Motors
GM
$81.3B
$12.3M 0.44%
300,000
– –
AMGN icon
42
CALL
Amgen
AMGN
$210B
$11.4M 0.41%
100,000
-100,000
-50% -$11.4M
BRFS
43
CALL
DELISTED
BRF SA
BRFS
$10.4M 0.37%
+500,000
New +$11.5M
MAS icon
44
CALL
Masco
MAS
$14.7B
$10.2M 0.37%
512,100
+227,600
+80% +$4.23M
GM icon
45
General Motors
GM
$81.3B
$10.2M 0.37%
+250,000
New +$9.45M
ZTS icon
46
CALL
Zoetis
ZTS
$32.8B
$9.81M 0.35%
300,000
– –
GS icon
47
Goldman Sachs
GS
$294B
$8.86M 0.32%
50,000
+10,000
+25% +$1.65M
MU icon
48
CALL
Micron Technology
MU
$880B
$8.7M 0.31%
+400,000
New +$7.78M
HOUS
49
DELISTED
Anywhere Real Estate
HOUS
$8.66M 0.31%
175,000
-25,000
-13% -$1.13M
ALNY icon
50
Alnylam Pharmaceuticals
ALNY
$38.2B
$8.04M 0.29%
+125,000
New +$7.46M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2013 Portfolio in Review

As of Q4 2013, Artal Group held 104 positions worth $2.79B, down 9.2% from $3.07B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Artal Group withdrew a net $93.2M in Q4 2013, closing 21 positions and reducing 21 holdings. Its most notable exit was Ford, an estimated $10.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Artal Group opened a new position in PHARMACYCLICS INC worth $17.5M.

  • Artal Group's largest Q4 2013 buy was PHARMACYCLICS INC: 165,000 shares worth $17.5M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $10.2M increase.
  • Artal Group's biggest Q4 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $21.4M.
  • Artal Group fully exited Ford in Q4 2013, selling an estimated $10.1M.
  • Artal Group's ten largest holdings make up 68% of its $2.79B portfolio in Q4 2013.
  • Artal Group opened 24 new positions and closed 21 in Q4 2013.
  • Artal Group's portfolio value fell 9.2% quarter-over-quarter to $2.79B.

Based on Artal Group's 13F filing for Q4 2013, filed 14 Feb 2014.